Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma

Technology in Cancer Research and Treatment

Volumn 9, Issue 2, 2010, Pages 179-189

  Wang, Yingmei ^a,b   Yang, Da ^a   Cogdell, David ^a   Hu, Limei ^a   Xue, Fengxia ^b   Broaddus, Russell ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

aCGH; Amplification; Deletion; Endometrial cancer; Pathway

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; RAF PROTEIN; RAS PROTEIN; WNT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CHROMOSOME 1; CHROMOSOME 10P; CHROMOSOME 10Q; CHROMOSOME 11; CHROMOSOME 11Q; CHROMOSOME 12; CHROMOSOME 14Q; CHROMOSOME 15Q; CHROMOSOME 16; CHROMOSOME 17Q; CHROMOSOME 18P; CHROMOSOME 19Q; CHROMOSOME 20; CHROMOSOME 21Q; CHROMOSOME 22; CHROMOSOME 2Q; CHROMOSOME 3P; CHROMOSOME 3Q; CHROMOSOME 5Q; CHROMOSOME 6; CHROMOSOME 7P; CHROMOSOME 8; CHROMOSOME 9; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; GENE AMPLIFICATION; GENE MUTATION; GENE NUMBER; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MICROARRAY ANALYSIS; ONCOGENE; SIGNAL TRANSDUCTION;

EID: 77952081984     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303461000900207     Document Type: Article

References (66)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M. J. Cancer statistics, 2009. CA Cancer J Clin 59, 225-249 (2009).
2. Sherman, M. E., Bur, M. E., Kurman, R. J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26, 1268-1274 (1995).
3. Weber, B. L. Cancer genomics. Cancer Cell 1, 37-47 (2002).
4. Levan, K., Partheen, K., Osterberg, L., Helou, K., Horvath, G. Chromosomal alterations in 98 endometrioid adenocarcinomas analyzed with comparative genomic hybridization. Cytogenet Genome Res 115, 16-22 (2006). (Pubitemid 44401347)
5. Hirasawa, A., Aoki, D., Inoue, J., Imoto, I., Susumu, N., Sugano, K., Nozawa, S., Inazawa, J. Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res 9, 5675-5682 (2003). (Pubitemid 37499490)
6. Oda, K., Stokoe, D., Taketani, Y., McCormick, F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65, 10669-10673 (2005). (Pubitemid 41713332)
7. Oda, K., Okada, J., Timmerman, L., Rodriguez-Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z. A., Shokat, K. M., McCormick, F. PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation Cancer Res 68, 8127-8136 (2008).
8. Catasus, L., Gallardo, A., Cuatrecasas, M., Prat, J. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 21, 131-139 (2008). (Pubitemid 351172164)
9. Catasus, L., Gallardo, A., Cuatrecasas, M., Prat, J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 22, 522-529 (2009).
10. Konecny, G. E., Santos, L., Winterhoff, B., Hatmal, M., Keeney, G. L., Mariani, A., Jones, M., Neuper, C., Thomas, B., Muderspach, L., Riehle, D., Wang, H. J., Dowdy, S., Podratz, K. C., Press, M. F. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 100, 89-95 (2009).
11. Bansal, N., Yendluri, V., Wenham, R. M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16, 8-13 (2009).
12. Ignatov, A., Bischoff, J., Schwarzenau, C., Krebs, T., Kuester, D., Herrmann, K., Costa, S. D., Roessner, A., Semczuk, A., Schneider-Stock, R. P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol 111, 365-371 (2008).
13. Yalta, T., Atay, L., Atalay, F., Caydere, M., Gonultas, M., Ustun, H. E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas. J Int Med Res 37, 163-168 (2009).
14. Saegusa, M., Hashimura, M., Kuwata, T., Hamano, M., Okayasu, I. Induction of p16INK4A mediated by beta-catenin in a TCF4-independent manner: implications for alterations in p16INK4A and pRb expression during trans-differentiation of endometrial carcinoma cells. Int J Cancer 119, 2294-2303 (2006). (Pubitemid 44546948)
15. Olshen, A. B., Venkatraman, E. S., Lucito, R., Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004). (Pubitemid 41180205)
16. van de Wiel, M. A., Kim, K. I., Vosse, S. J., van Wieringen, W. N., Wilting, S. M., Ylstra, B. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23, 892-894 (2007).
17. Hayes, M. P., Wang, H., Espinal-Witter, R., Douglas, W., Solomon, G. J., Baker, S. J., Ellenson, L. H. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12, 5932-5935 (2006). (Pubitemid 44703751)
18. Velasco, A., Bussaglia, E., Pallares, J., Dolcet, X., Llobet, D., Encinas, M., Llecha, N., Palacios, J., Prat, J., Matias-Guiu, X. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 37, 1465-1472 (2006). (Pubitemid 44584324)
19. Carmon, K. S., Loose, D. S. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res 6, 1017-1028 (2008).
20. Lax, S. F., Kendall, B., Tashiro, H., Slebos, R. J., Hedrick, L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88, 814-824 (2000). (Pubitemid 30091101)
21. Tu, Z., Gui, L., Wang, J., Li, X., Sun, P., Wei, L. Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor. Gynecol Oncol 101, 274-279 (2006).
22. O'Toole, S. A., Dunn, E., Sheppard, B. L., Klocker, H., Bektic, J., Smyth, P., Martin, C., Sheils, O., O'Leary, J. J. Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays. Int J Gynecol Cancer 16, 834-842 (2006).
23. Mutter, G. L. Pten, a protean tumor suppressor. Am J Pathol 158, 1895-1898 (2001).
24. Mutter, G. L., Lin, M. C., Fitzgerald, J. T., Kum, J. B., Baak, J. P., Lees, J. A., Weng, L. P., Eng, C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92, 924-930 (2000). (Pubitemid 30429193)
25. Maurice-Duelli, A., Ndoye, A., Bouali, S., Leroux, A., Merlin, J. L. Enhanced cell growth inhibition following PTEN nonviral gene transfer using polyethylenimine and photochemical internalization in endometrial cancer cells. Technol Cancer Res Treat 3, 459-465 (2004). (Pubitemid 39392001)
26. Sexton, E., Van Themsche, C., LeBlanc, K., Parent, S., Lemoine, P., Asselin, E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer 5, 45 (2006). (Pubitemid 44712389)
27. Gao, J., Tian, J., Lv, Y., Shi, F., Kong, F., Shi, H., Zhao, L. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci 100, 389-395 (2009).
28. Sheng, S., Qiao, M., Pardee, A. B. Metastasis and AKT activation. J Cell Physiol 218, 451-454 (2009).
29. Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., Gray, J. W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21, 99-102 (1999). (Pubitemid 29036292)
30. Massion, P. P., Kuo, W. L., Stokoe, D., Olshen, A. B., Treseler, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., Albertson, D. G., Jablons, D. M., Gray, J. W. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62, 3636-3640 (2002). (Pubitemid 34728838)
31. Estilo, C. L., P, O. C., Ngai, I., Patel, S. G., Reddy, P. G., Dao, S., Shaha, A. R., Kraus, D. H., Boyle, J. O., Wong, R. J., Pfister, D. G., Huryn, J. M., Zlotolow, I. M., Shah, J. P., Singh, B. The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue. Clin Cancer Res 9, 2300-2306 (2003). (Pubitemid 36687656)
32. Ma, Y. Y., Wei, S. J., Lin, Y. C., Lung, J. C., Chang, T. C., Whang-Peng, J., Liu, J. M., Yang, D. M., Yang, W. K., Shen, C. Y. PIK3CA as an oncogene in cervical cancer. Oncogene 19, 2739-2744 (2000).
33. Crowell, J. A., Steele, V. E., Fay, J. R. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 6, 2139-2148 (2007).
34. Shtilbans, V., Wu, M., Burstein, D. E. Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann Diagn Pathol 12, 153-160 (2008). (Pubitemid 351312912)
35. Yang, Z. Z., Tschopp, O., Baudry, A., Dummler, B., Hynx, D., Hemmings, B. A. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 32, 350-354 (2004). (Pubitemid 38582126)
36. Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., Roth, R. A. Up-regulation of Akt3 in estrogen receptordeficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274, 21528-21532 (1999). (Pubitemid 129519688)
37. Arboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala, R., Danino, M., Karlan, B. Y., Slamon, D. J. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63, 196-206 (2003). (Pubitemid 36070440)
38. Irie, H. Y., Pearline, R. V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, N., Natesan, S., Brugge, J. S. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 171, 1023-1034 (2005). (Pubitemid 41815834)
39. Gagnon, V., Mathieu, I., Sexton, E., Leblanc, K., Asselin, E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94, 785-795 (2004). (Pubitemid 39194476)
40. Robinson, D. R., Zylstra, C. R., Williams, B. O. Wnt signaling and prostate cancer. Curr Drug Targets 9, 571-580 (2008).
41. Guillen-Ahlers, H. Wnt signaling in renal cancer. Curr Drug Targets 9, 591-600 (2008).
42. Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., Fearon, E. R., Cho, K. R. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11, 321-333 (2007). (Pubitemid 46518315)
43. Wang, Y., Hanifi-Moghaddam, P., Hanekamp, E. E., Kloosterboer, H. J., Franken, P., Veldscholte, J., van Doorn, H. C., Ewing, P. C., Kim, J. J., Grootegoed, J. A., Burger, C. W., Fodde, R., Blok, L. J. Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 15, 5784-5793 (2009).
44. Wagner, J., Lehmann, L. Estrogens modulate the gene expression of Wnt-7a in cultured endometrial adenocarcinoma cells. Mol Nutr Food Res 50, 368-372 (2006).
45. Mo, B., Vendrov, A. E., Palomino, W. A., DuPont, B. R., Apparao, K. B., Lessey, B. A. ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biol Reprod 75, 387-394 (2006). (Pubitemid 44268073)
46. Wormke, M., Castro-Rivera, E., Chen, I., Safe, S. Estrogen and aryl hydrocarbon receptor expression and crosstalk in human Ishikawa endometrial cancer cells. J Steroid Biochem Mol Biol 72, 197-207 (2000). (Pubitemid 32156529)
47. Ueda, M., Toji, E., Nunobiki, O., Izuma, S., Okamoto, Y., Torii, K., Noda, S. Mutational analysis of the BRAF gene in human tumor cells. Hum Cell 21, 13-17 (2008). (Pubitemid 351499179)
48. Jovanovic, B., Egyhazi, S., Eskandarpour, M., Ghiorzo, P., Palmer, J. M., Bianchi Scarra, G., Hayward, N. K., Hansson, J. Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations. J Invest Dermatol (2009).
49. Oikonomou, E., Kosmidou, V., Katseli, A., Kothonidis, K., Mourtzoukou, D., Kontogeorgos, G., Andera, L., Zografos, G., Pintzas, A. TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors. Int J Cancer 125, 2127-2135 (2009).
50. Pijnenborg, J. M., Dam-de Veen, G. C., Kisters, N., Delvoux, B., van Engeland, M., Herman, J. G., Groothuis, P. G. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. Ann Oncol 18, 491-497 (2007). (Pubitemid 46359628)
51. Kawaguchi, M., Yanokura, M., Banno, K., Kobayashi, Y., Kuwabara, Y., Kobayashi, M., Nomura, H., Hirasawa, A., Susumu, N., Aoki, D. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int J Oncol 34, 1541-1547 (2009).
52. Salvesen, H. B., Kumar, R., Stefansson, I., Angelini, S., MacDonald, N., Smeds, J., Jacobs, I. J., Hemminki, K., Das, S., Akslen, L. A. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer 115, 930-934 (2005). (Pubitemid 40791834)
53. Feng, Y. Z., Shiozawa, T., Miyamoto, T., Kashima, H., Kurai, M., Suzuki, A., Konishi, I. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 11, 6133-6138 (2005). (Pubitemid 41262939)
54. Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., Drew, L., Haber, D. A., Settleman, J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68, 4853-4861 (2008).
55. Fedorov, L. M., Papadopoulos, T., Tyrsin, O. Y., Twardzik, T., Gotz, R., Rapp, U. R. Loss of p53 in craf-induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch. Cancer Res 63, 2268-2277 (2003). (Pubitemid 36538636)
56. Hagemann, C., Gloger, J., Anacker, J., Said, H. M., Gerngras, S., Kuhnel, S., Meyer, C., Rapp, U. R., Kammerer, U., Vordermark, D., Flentje, M., Roosen, K., Vince, G. H. RAF expression in human astrocytic tumors. Int J Mol Med 23, 17-31 (2009).
57. Le Mellay, V., Houben, R., Troppmair, J., Hagemann, C., Mazurek, S., Frey, U., Beigel, J., Weber, C., Benz, R., Eigenbrodt, E., Rapp, U. R. Regulation of glycolysis by Raf protein serine/threonine kinases. Adv Enzyme Regul 42, 317-332 (2002). (Pubitemid 35033546)
58. Mazurek, S., Drexler, H. C., Troppmair, J., Eigenbrodt, E., Rapp, U. R. Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res 27, 3963-3971 (2007).
59. Mercer, K., Chiloeches, A., Huser, M., Kiernan, M., Marais, R., Pritchard, C. ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf. Oncogene 21, 347-355 (2002). (Pubitemid 34123797)
60. Castano, J., Davalos, V., Schwartz, S., Jr., Arango, D. EPH receptors in cancer. Histol Histopathol 23, 1011-1023 (2008).
61. Kamat, A. A., Coffey, D., Merritt, W. M., Nugent, E., Urbauer, D., Lin, Y. G., Edwards, C., Broaddus, R., Coleman, R. L., Sood, A. K. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115, 2684-2692 (2009).
62. Takai, N., Miyazaki, T., Fujisawa, K., Nasu, K., Miyakawa, I. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer. Oncol Rep 8, 567-573 (2001). (Pubitemid 33758456)
63. Berclaz, G., Karamitopoulou, E., Mazzucchelli, L., Rohrbach, V., Dreher, E., Ziemiecki, A., Andres, A. C. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 14, 220-226 (2003). (Pubitemid 36305433)
64. Chiu, S. T., Chang, K. J., Ting, C. H., Shen, H. C., Li, H., Hsieh, F. J. Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis 30, 1475-1486 (2009).
65. Kang, J. U., Koo, S. H., Kwon, K. C., Park, J. W., Kim, J. M. Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 9, 237 (2009).
66. Berardi, A. C., Marsilio, S., Rofani, C., Salvucci, O., Altavista, P., Perla, F. M., Diomedi-Camassei, F., Uccini, S., Kokai, G., Landuzzi, L., McDowell, H. P., Dominici, C. Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. Anticancer Res 28, 763-769 (2008). (Pubitemid 351578919)